This Dow Jones headline alone would send seismic tremors in the CV world!!
Its worth noting that from Novartis' perspective, paraphrasing @The Yankee...
Think about how perfectly Entresto would complement MESO's Revascor. This would make for a perfect end-to-end treatment in heart disease. Now throw in their recent purchase of the LDL-C reducing drug Inclisiran and you have just found your "one stop shop " in an incredibly powerful combination treatment for the number one killer in the world - heart disease.
If I were Novartis, I would be revising my cheque for the upfront payment and terms of the partnership to now include Revascor in the mix.
Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF, page-112
-
- There are more pages in this discussion • 652 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
96.0¢ |
Change
0.025(2.67%) |
Mkt cap ! $1.096B | |||
| Open | High | Low | Value | Volume |
| 95.0¢ | 96.5¢ | 94.0¢ | $1.231M | 1.291M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 94461 | 95.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 96.0¢ | 61151 | 6 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |